CARRA and the Duke Clinical Research Institute (DCRI) have launched the second phase of the CARRA Registry, a registry of children and young adults with pediatric-onset rheumatic conditions such as juvenile idiopathic arthritis (JIA). The scope of the former registry, the CARRA Legacy Registry, is being expanded to help researchers learn more about the progression of the disease and medication safety.
The new CARRA Registry provides additional opportunities for research through identification of subjects eligible for future studies and by serving as a data repository. The Registry is a cornerstone of CARRA and provides disease and treatment data on children with a variety of rheumatic diseases. CARRA aims to make it possible for all affected children in North America to have the opportunity to participate in meaningful and high quality clinical and translational research.
As of Winter 2020, 70 CARRA Registry sites are participating across the US and Canada with over 10,000 patients enrolled.
The coordinating center is the Duke Clinical Research Institute (DCRI).
The lead investigators are Yukiko Kimura, MD (Hackensack University Medical Center, NJ), Laura Schanberg, MD (Duke University) and Timothy Beukelman, MD MCSE (University of Alabama at Birmingham).